Published in Pharma Law Weekly, April 25th, 2006
MIVT is also developing a novel stroke-prevention device through its wholly owned subsidiary, SagaX Inc., located in Herzlyia, Israel. SagaX is a developer of advanced biomedical technology, including the aortic embolic protection device (AEPD). The AEPD is a unique and proprietary filter/deflector device designed specifically to prevent cardioembolic stroke following heart surgery. SagaX...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly